CurifyLabs raises $14 million in Series A funding

Key Takeaways

• CurifyLabs secures $14 million in Series A funding to expand US operations and enhance product innovation
• The company's Compounding System Solution (CSS) utilizes 3D printing technology to automate personalized medication preparation
• CurifyLabs' technology is used by pharmacies in 21 US states and across Europe, with the capacity to produce thousands of doses daily
• The funding will support the development of the CurifyLabs platform, including the PharmaPrinter Aurum, which compounds up to 9 times faster than manual processes

Introduction to CurifyLabs

CurifyLabs, a leading provider of automated compounding solutions, has announced the successful closure of a $14 million Series A funding round. Co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures, this investment will drive the expansion of US operations, strengthen supply chain infrastructure, and accelerate product innovation.

The Compounding System Solution (CSS)

The CSS is a proprietary technology that combines advanced software, GMP-manufactured excipient bases, and 3D printing to automate the preparation of personalized medications. With built-in quality control processes, the CSS produces tailored doses and dosage forms with greater precision and speed than traditional manual processes. This technology has been adopted by pharmacies in 21 US states and across Europe, with the capacity to produce thousands of doses daily.

Comparison of Compounding Technologies

Investment and Growth

The $14 million funding will support the ongoing development of the CurifyLabs platform, including the PharmaPrinter Aurum, which has the capacity to compound up to 9 times faster than manual processes. This investment will also enable the company to strengthen its supply chain infrastructure, ensuring that its growing network of pharmacy partners has access to the necessary resources and support.

Bottom Line

In conclusion, CurifyLabs' successful Series A funding round marks a significant milestone in the company's growth and development. With its innovative Compounding System Solution and commitment to quality and compliance, CurifyLabs is poised to revolutionize the pharmaceutical compounding industry. As the company continues to expand its operations and enhance its product offerings, it is likely to have a profound impact on the way personalized medications are prepared and dispensed.